CTC BIO’s premature ejaculation treatment to enter Taiwan

CTC BIO, a Korean pharmaceutical company, said it signed an exclusive supply agreement with Chifu, a Taiwanese pharmaceutical distributor, for One- two Tab., its premature ejaculation treatment.

Chifu, established in 1961, has a long history in the distribution of neurological pharmaceuticals and has been expanding its portfolio to include pain management and neuropathic treatments. The two companies have previously collaborated on a cannabidiol (CBD) oral dissolving film (ODF) in 2021, marking a strong foundation for this new venture.

Following its launch in Korea on July 30, CTC BIO has been eyeing the drug’s launch in the global market.

The company plans to secure approval from the Taiwan Food and Drug Administration (TFDA) before commencing full-scale distribution in the region.

CTC BIO expects that the agreement will generate a minimum revenue of $30 million (40.9 billion won) over the next five years in Taiwan.

“This agreement with Chifu marks the beginning of our global expansion for One-two Tab.,” a company official said. “We aim to leverage the Taiwanese market as a strategic entry point into Asia, followed by North America, Europe, and beyond.”

CTC BIO CEO Kim Young-deok also said, “Our partnership with Chifu is a testament to the excellence, market potential, and convenience of our One-two Tab.,” he said.

The company will continue its efforts to quickly increase our market share in Taiwan’s urology sector, Kim added.